Catena’s CysTyr™ Conjugation Platform
Unlocks Next-Generation
Multi-Payload Conjugates™
Catena’s unique platform enables never-before-possible therapeutic structures and revolutionizes antibody-drug conjugates (ADCs)
With an initial focus on solid tumors with high unmet needs, our Multi-Payload Conjugates (MPCs) deliver dual payloads and show preclinical superiority to current standards of care.
CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024
San Diego, CACatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM
January 4, 2024
Berkeley, CA